多汗症治療の世界市場 (2022-2028年)：治療法 (ボツリヌス毒性A・イオン導入)・タイプ (原発性局所性多汗症・二次性全身性多汗症)・エンドユーザー (病院・外来) 別の規模・シェア・成長分析・予測

世界の多汗症治療の市場規模は、2021年の12億米ドルから、予測期間中は6.2％のCAGRで推移し、2028年には20億米ドルの規模に成長すると予測されています。

二次性多汗症疾患の発生率の上昇や、参入企業によるR&D投資の増加が同市場の成長を後押ししている主な理由です。

当レポートでは、世界の多汗症治療の市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

親市場の分析

• 市場概要
• 市場規模
• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題
• 主要な市場の洞察
• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場エコシステム
• IP分析
• トレード分析
• スタートアップ分析
• 原材料分析
• イノベーションマトリックス
• パイプライン製品分析
• マクロ経済指標
• 主要投資分析
• 主な成功要因
• 競合の程度
• 市場力学と展望
• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題
• 規制状況
• ポーターの分析
• 将来のディスラプションに関するSkyquestの特別な洞察
• 世界の多汗症治療市場：治療法別
• 市場概要
• ボツリヌス毒素A
• イオン導入
• 外科的治療
• 局所治療
• 汗腺の非外科的マイクロ波エネルギー破壊
• その他

世界の多汗症治療市場：タイプ別

• 市場概要
• 原発性局所性多汗症
• 二次性全身性多汗症
• 世界の多汗症治療市場：エンドユーザー別
• 市場概要
• 病院
• 外来
• 外科センター
• その他
• 世界の多汗症治療市場の規模：地域別
• 市場概要
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東およびアフリカ
• 競合情勢
• 主要5社の比較
• 主要企業の市場ポジショニング
• 主要企業の採用戦略
• 主要成功戦略
• 市場における最近の活動
• 主要企業の市場シェア
• 主な企業プロファイル
• Allergan PLC
• Brickell Biotech Inc.
• Cynosure
• Dermadry Laboratories lnc.
• Dermira Inc.
• GlaxoSmithKline PLC
• Miramar Labs, Inc.
• Sesderma
• Ulthera Inc.

Global hyperhidrosis treatment market was valued at USD 1.2 billion in 2021 and is expected to reach USD 2 billion by 2028. The market is anticipated to grow at a CAGR of 6.2% during the forecast period (2022-2028).

The first line of defence in the battle against hyperhidrosis is antiperspirants and topical drugs. Hyperhidrosis, however, has no known treatment at this time. In recent years, there has been a lot of activity in the development of new products and technology. Businesses have invested in this industry as a result of the public's growing awareness of potential therapies and patients' need for cutting-edge techniques.

The rising incidence of secondary hyperhidrosis diseases and market participants increasing their R&D investment are the main reasons fueling the market expansion for hyperhidrosis therapeutics. According to a study by Jared Brackenrich that was published in the National Library of Medicine in October 2021, this ailment is thought to occur quite frequently in the United States, with an estimated 3% incidence. Hyperhidrosis may impair social, psychological, emotional, and vocational functioning. Thus, it is predicted that the increasing prevalence of hyperhidrosis will increase the need for treatment and, as a result, accelerate market expansion.

A possible therapy pipeline for the ailment could have an effect on market growth in addition to favourable reimbursement policies, higher rates of anxiety and depression, and increased public awareness of hyperhidrosis. For instance, Brickell Biotech Inc. released encouraging topline findings from the Phase 3 pivotal Cardigan I and Cardigan II investigations in October 2021. These studies assessed the effectiveness of 15% sofpironium bromide gel applied topically once daily in patients with primary axillary hyperhidrosis.

Top-down and bottom-up approaches were used to estimate and validate the size of Asia Pacific Hyperhidrosis treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

The market is divided into segments based on end user, area, kind of hyperhidrosis, and type of treatment. The market is segmented by type of treatment, including non-surgical microwave energy destruction of sweat glands, lontophoresis, surgical treatment, tropical treatment, and botulinum toxic A. There are two types of hyperhidrosis: primary focused and secondary widespread. It is separated into hospitals, ambulatory, surgical centres, and other facilities according on the end user (dermatology clinics & cosmetic centers). It is separated into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa based on region.

Driver

The effects of hyperhidrosis therapy based on radiofrequency microneedling on patients with the ailment are being studied by medical professionals. Stakeholders are attempting to discover whether fractional microneedle radiofrequency treatment offers long-term benefits, particularly for patients with primary axillary hyperhidrosis. These studies' analysis of the hyperhidrosis disease severity scale (HDSS) revealed that patients' conditions dramatically improved after taking medication.

Another hyperhidrosis treatment that is gaining popularity among patients is tap water iontophoresis, which involves transporting an ionised material through the skin using a direct electric current. In numerous treatment trials, patients with plantar and palmar hyperhidrosis demonstrated significant improvements. Patients are able to live better lifestyles and perspire significantly less as a result of these positive effects.

The most recent market-related R&D projects are gaining popularity on a global basis. For instance, Brickell Biotech Inc. released upbeat topline results from the Phase 3 pivotal Cardigan I and II studies, which examined the efficacy of 15% sofpironium bromide gel applied topically once daily in patients with primary axillary hyperhidrosis. This quickens market growth.

Restraints

Particularly botulinum toxin injections have a lot of drawbacks, such as its transient efficacy in people who grow less tolerant to the dosage as they become accustomed to it. Another issue harming the market for hyperhidrosis treatments is the financial load and psychological distress that patients endure as a result of many medical insurance companies not covering hyperhidrosis treatment.

Market Trends

OnabotulinumtoxinA can be used to treat excessive sweating in the armpits, hands, feet, head, face, and other relatively small body areas, according to an article that was published in the International Hyperhidrosis Society in October 2020. (such under the breasts). When used to treat excessive sweating beneath the arms, Botox has been shown to reduce sweating by 82-87%. The effects of treatment often begin to apparent two to four days after the procedure and reach their peak two weeks later. Despite typically lasting 4 to 12 months, dryness can continue up to 14 months, according to some research.

Several studies have shown how effective it is at reducing anxiety. A study from 2021 that was published in the journal Scientific Reports found that persons who had Botox injections at four different locations experienced significantly less anxiety than those who received other treatments for the same conditions. In Botox patients, anxiety was seen to be reduced by 22-72%.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune
• Research Methodology
• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Key Market Insights
• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition
• Market Dynamics & Outlook
• Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Regulatory Landscape
• Porters Analysis
• Competitive rivalry
• Threat of Substitute Products
• Bargaining Power of Buyers
• Threat of New Entrants
• Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
• Political Impact
• Economic Impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact
• Global Hyperhidrosis Treatment Market by Treatment
• Market Overview
• Botulinum toxic A
• lontophoresis
• surgical treatment
• tropical treatment
• non-surgical microwave energy destruction of sweat glands
• others

Global Hyperhidrosis Treatment Market by Type

• Market Overview
• Primary focal
• secondary generalized
• Global Hyperhidrosis Treatment Market by End User
• Market Overview
• Hospitals
• ambulatory
• surgical centers
• others
• Global Hyperhidrosis Treatment Market Size by Region
• Market Overview
• North America
• USA
• Canada
• Europe
• Germany
• Spain
• France
• UK
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC Countries
• South Africa
• Rest of MEA
• Competitive Landscape
• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
• By Development
• By Company
• By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021
• Key Company Profiles
• Allergan PLC (Ireland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Brickell Biotech Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Cynosure (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Dermadry Laboratories lnc. (Canada)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Dermira Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• GlaxoSmithKline PLC (UK)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Miramar Labs, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Sesderma (Spain)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
• Ulthera Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments